256 related articles for article (PubMed ID: 15700310)
1. Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro.
Festuccia C; Gravina GL; Angelucci A; Millimaggi D; Muzi P; Vicentini C; Bologna M
Int J Cancer; 2005 Jul; 115(4):630-40. PubMed ID: 15700310
[TBL] [Abstract][Full Text] [Related]
2. Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer.
Sirotnak FM; She Y; Lee F; Chen J; Scher HI
Clin Cancer Res; 2002 Dec; 8(12):3870-6. PubMed ID: 12473602
[TBL] [Abstract][Full Text] [Related]
3. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
Quéro L; Giocanti N; Hennequin C; Favaudon V
Prostate; 2010 Mar; 70(4):401-11. PubMed ID: 19902473
[TBL] [Abstract][Full Text] [Related]
4. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
Gravina GL; Festuccia C; Millimaggi D; Dolo V; Tombolini V; de Vito M; Vicentini C; Bologna M
Prostate; 2008 May; 68(7):793-801. PubMed ID: 18324645
[TBL] [Abstract][Full Text] [Related]
5. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
Hara T; Miyazaki J; Araki H; Yamaoka M; Kanzaki N; Kusaka M; Miyamoto M
Cancer Res; 2003 Jan; 63(1):149-53. PubMed ID: 12517791
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines.
Koukourakis MI; Kakouratos C; Kalamida D; Mitrakas A; Pouliliou S; Xanthopoulou E; Papadopoulou E; Fasoulaki V; Giatromanolaki A
Anticancer Drugs; 2018 Apr; 29(4):323-333. PubMed ID: 29381490
[TBL] [Abstract][Full Text] [Related]
7. The antiandrogen bicalutamide activates the androgen receptor (AR) with a mutation in codon 741 through the mitogen activated protein kinase (MARK) pathway in human prostate cancer PC3 cells.
Terakawa T; Miyake H; Kumano M; Sakai I; Fujisawa M
Oncol Rep; 2010 Nov; 24(5):1395-9. PubMed ID: 20878136
[TBL] [Abstract][Full Text] [Related]
8. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
[TBL] [Abstract][Full Text] [Related]
9. Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.
Takeda K; Hara N; Nishiyama T; Tasaki M; Ishizaki F; Tomita Y
BMC Cancer; 2016 May; 16():332. PubMed ID: 27225190
[TBL] [Abstract][Full Text] [Related]
10. Antagonist/agonist balance of the nonsteroidal antiandrogen bicalutamide (Casodex) in a new prostate cancer model.
Hobisch A; Hoffmann J; Lambrinidis L; Eder IE; Bartsch G; Klocker H; Culig Z
Urol Int; 2000; 65(2):73-9. PubMed ID: 11025427
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures.
Vicentini C; Festuccia C; Gravina GL; Angelucci A; Marronaro A; Bologna M
J Cancer Res Clin Oncol; 2003 Mar; 129(3):165-74. PubMed ID: 12712332
[TBL] [Abstract][Full Text] [Related]
12. Gefitinib and bicalutamide show synergistic effects in primary cultures of prostate cancer derived from androgen-dependent naive patients.
Festuccia C; Gravina GL; Muzi P; Biordi L; Ronchi P; Martella O; Vicentini C; Bologna M
Oncol Rep; 2007 Nov; 18(5):1321-7. PubMed ID: 17914592
[TBL] [Abstract][Full Text] [Related]
13. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.
Yoshida T; Kinoshita H; Segawa T; Nakamura E; Inoue T; Shimizu Y; Kamoto T; Ogawa O
Cancer Res; 2005 Nov; 65(21):9611-6. PubMed ID: 16266977
[TBL] [Abstract][Full Text] [Related]
14. Bicalutamide demonstrates biologic effectiveness in prostate cancer cell lines and tumor primary cultures irrespective of Her2/neu expression levels.
Gravina GL; Festuccia C; Millimaggi D; Tombolini V; Dolo V; Vicentini C; Bologna M
Urology; 2009 Aug; 74(2):452-7. PubMed ID: 19285710
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
16. Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer.
Colquhoun AJ; Venier NA; Vandersluis AD; Besla R; Sugar LM; Kiss A; Fleshner NE; Pollak M; Klotz LH; Venkateswaran V
Prostate Cancer Prostatic Dis; 2012 Dec; 15(4):346-52. PubMed ID: 22614062
[TBL] [Abstract][Full Text] [Related]
17. Synergic effects of the cyclin-dependent kinase (CDK) inhibitor olomoucine and androgen-antagonist bicalutamide on prostatic cancer cell lines.
Knillová J; Bouchal J; Hlobilková A; Strnad M; Kolár Z
Neoplasma; 2004; 51(5):358-67. PubMed ID: 15640940
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effects of carnertinib in castration resistant prostate cancer models: a comparative study with erlotinib.
Gravina GL; Marampon F; Piccolella M; Biordi L; Ficorella C; Motta M; Jannini EA; Tombolini V; Festuccia C
Prostate; 2011 Oct; 71(14):1481-91. PubMed ID: 21446006
[TBL] [Abstract][Full Text] [Related]
19. The development of Casodex (bicalutamide): preclinical studies.
Furr BJ
Eur Urol; 1996; 29 Suppl 2():83-95. PubMed ID: 8717469
[TBL] [Abstract][Full Text] [Related]
20. Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity.
Kokontis JM; Hsu S; Chuu CP; Dang M; Fukuchi J; Hiipakka RA; Liao S
Prostate; 2005 Dec; 65(4):287-98. PubMed ID: 16015608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]